ANTICOAGULANTS Flashcards

1
Q

antiCLOTTING drugs includes the following groups…

A
  1. antiCOAGULANT drugs → effective in treatment of venous & arterial thrombosis
  2. thrombolytics → effective in treatment of venous & arterial thrombosis
  3. antiPLATELET drugs → used primarily for treatment of arterial disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ANTICOAGULANTS:

A
  1. heparin
  2. LMW fraction heparins
  3. fondaparinux
  4. vit. K antagonists
  5. direct THROMBIN inhibitors
  6. factor X inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

heparin → mechanism of action:

A

bind to antithrombin III (ATIII) → inactivates coagulation factors (esp. factor X = stuart factor) & thrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

heparin → pharmacokinetics:

A
  1. IV administration → ass. with ACUTE states
  2. SC administration → more long-term treatment
  3. monitored with aPTT test
  4. safe in PREGNANCY
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

heparin → indications:

A

acute thromboembolic disorders:

  1. peripheral and pulmonary embolism
  2. venous thrombosis
  3. coagulopathies (DIC)

prophylaxis:

  1. arterial and heart surgery
  2. blood transfusion
  3. renal dialysis
  4. prevent embolization in atrial fibrillation
  5. prevent DVT & pulmonary embolism
  6. heart attacks
  7. alright to use during PREGNANCY (compared to warfarin which cross the placenta → may cause bleeding to the fetus)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

heparin → CONTRAindications:

A
  1. hypersensitivity
  2. bleeding disorders
  3. alcoholism
  4. recent surgery of brain, eye, spinal cord
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

heparin → side effects:

A
  1. most common = bleeding
  2. two types of heparin-induced thrombocytopenias (HIT)
  3. prolonged use → ass. with osteoporosis
  4. hyperkalemia → suppression of aldosterone secretion
  5. chills, fever
  6. anaphylactic shock
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

LMW heparins:

A
  1. enoxaparin
  2. dalteparin
  3. tinzaparin
  4. bemiparin
  5. certoparin
  6. nadroparin
  7. parnaparin
  8. reviparin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LMW heparins → mechanism of action:

A

inactivates active factor X (Xa/stuart factor) → unlike heparin the LMW heparins cannot inactivate thrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

LMW heparins → pharmacokinetics:

A
  • SC administration → 1-2/day

- monitoring in → obese, renal impairment & PREGNANCY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

LMW heparins → indications:

A
  1. PREVENTION of thromboembolism ass. with abdominal surgery, knee or hip replacement
  2. ischemic complications of unstable angina, acute coronary syndrome, angioplasty
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

fondaparinux → mechanism of action:

A
  1. even more selective factor Xa inhibitor
  2. binds antithrombin → acc. inhibition of factor Xa
  3. in contrast to heparin → fondaparinux does NOT inhibit thrombin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

fondaparinux → pharmacokinetics:

A

given SC once daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

fondaparinux → indications:

A
  1. treatment & prophylaxis of DVT

2. prevention of thromboembolism in hip fracture, hip or knee replacement surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

fondaparinux → side effects:

A
  1. bleeding (no reversal treatment)

2. HIT less likely than with heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

VIT. K antagonists:

A
  1. warfarin

2. coumarin derivatives

17
Q

VIT. K antagonists → mechanism of action:

A
  1. inhibit synthesis of factor II, VII, IX & X in liver

2. inhibit synthesis of protein C & S → endogenous anticoagulants that inactivate V & VIII + promote fibrinolysis

18
Q

VIT. K antagonists → pharmacokinetics:

A
  1. ORALLY
  2. well absorbed from GIT → excreted in urine
  3. max. effect after 3-5 days of treatment ≈ 1 week
  4. INR test
  5. CYP450 metabolism
19
Q

VIT. K antagonists → indications:

A
  1. treatment & prevention of → DVT & PE
  2. ischemic heart disease
  3. rheumatic heart disease
  4. pulmonary embolism
  5. lifelong use in pat. with artificial heart valves (STROKE prevention)
  6. protein C & S deficiency, antiphospholipid syndrome
20
Q

VIT. K antagonists → side effects:

A
  1. hemorrhage
  2. necrosis & skin lesions (rare)
  3. purple toe syndrome (rare)
  4. teratogenic → NOT safe in pregnancy!!
21
Q

direct THROMBIN inhibitors:

A
  1. hirudin (not often used)
  2. lepirudin
  3. bivalirudin
  4. argatroban
  5. dabigatran (ORALLY)
22
Q

direct THROMBIN inhibitors → mechanism of action:

A
  1. hirudin, lepirudin, bivalirudin → reversibly inhibit catalytic site of both free & clot-bound thrombin
  2. argatroban → DIRECT thrombin inhibitor
  3. dabigatran → potent, competitive, REVERSIBLE inhibitor of thrombin
23
Q

direct THROMBIN inhibitors → pharmacokinetics:

A
  1. hirudin, lepirudin, bivalirudin → PARENTERAL / IV
  2. argatroban:
    1. PARENTERAL/IV
    2. metabolized in the liver
    3. requires monitoring → aPTT etc.
  3. dabigatran:
    1. ORALLY (= the FIRST orally active direct thrombin inhibitor!!)
    2. does NOT interact with food or most other drugs → therefore do NOT require monitoring
24
Q

direct THROMBIN inhibitors → indications:

A
  1. hirudin, lepirudin, bivalirudin → alternative to heparin in pat. undergoing PCI who have/at risk for developing HIT (heparin-induced thrombocytopenia)
  2. argatroban → prophylaxis or treatment of venous thromboembolism in pat. with HIT
  3. dabigatran → reduce the risk of stroke & systemic embolism in pat. with non-valvular atrial fibrillation
25
Q

direct THROMBIN inhibitors → side effects:

A
  1. hirudin, lepirudin, bivalirudin → bleeding
  2. argatroban → bleeding
  3. dabigatran:
    1. bleeding
    2. use with caution in renal impairment & pat. >75y
    3. dyspepsia, esophagitis, abdominal pain, GI bleeding
26
Q

factor X inhibitors:

A
  1. rivaroxaban

2. apixaban

27
Q

factor X inhibitors → pharmacokinetics:

A

ORALLY

28
Q

factor X inhibitors → indications:

A
  1. rivaroxaban → prevention of DVT, clots, PE after knee or hip surgery
  2. apixaban:
    1. stroke prevention in atrial fibrillation
    2. prevention & treatment of DVT, prevention of CV events in MI
29
Q

factor X inhibitors → side effects:

A
  1. bleeding

2. avoid abrupt discontinuation